Clinical Trial Update: Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study of amifampridine phosphate in MuSK antibody-positive and acetylcholine receptor antibody-positive myasthenia gravis was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acetylcholine Receptor Antibody-positive Myasthenia Gravis
• Musk Antibody-positive Myasthenia Gravis

Drugs mentioned

• Amifampridine phosphate (amifampridine phosphate)

Snippet

Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Myasthenia Gravis, MuSK, AChR Myasthenia Gravis | Phase 3 | Status: TERMINATED | Results posted: 2024-05-07